Medication info
Diorban Tablet 80 mg (Valsartan)

Diorban Tablet 80 mg (Valsartan)

Prescription medicationTabletOral
Ingredient · strength
Valsartan›80mg / 1 tablet
Manufacturer / importer
Allico Pharmaceutical Co., Ltd.
Appearance
Pink round film-coated tablet
Packaging
30 tablets per bottle, 100 tablets per bottle
Approval status
Active

MFDS item code 200809324 · Notified 2008.09.08 · Insurance code 656002670

Summary

Main use
Treatment of essential hypertension and heart failure; reduction in the risk of death after myocardial infarction
Who takes it
Adults · Children
Adult dose
1. Essential hypertension Take with water during or between meals. If possible, take it at the same time each day (e.g., in the morning). 1) Adults: The recommended dose is valsartan 80 mg orally once daily, regardless of sex or race. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg daily or a diuretic may be given concomitantly. If further blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg daily. 2) Older adults (75 years and older): Start treatment with this medicine at 40 mg once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is required. (2) Creatinine clearance 10 ∼ 20 mL/min: Start treatment with this medicine at 40 mg once daily. (3) Creatinine clearance below 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with volume depletion: In patients with volume depletion (e.g., those taking high doses of diuretics whose dose cannot be reduced), start treatment with this medicine at 40 mg once daily. 5) Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, start treatment with this medicine at 40 mg once daily; do not exceed 80 mg daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg orally twice daily. The dose may be increased to 80 mg or 160 mg per dose. When administering a diuretic concomitantly, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, administered in divided doses. Triple combination therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours after the onset of myocardial infarction. The recommended starting dose is 20 mg twice daily, followed over several weeks by dose titration, according to the patient's tolerability, to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytics, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with ACE inhibitors is not recommended. 4. Patients with renal impairment: No dose adjustment is required for creatinine clearance of 10 mL/min or higher; however, do not administer this medicine to patients with creatinine clearance below 10 mL/min or to patients on dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If administering 80 mg or more daily, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.
Child dose
6) Children: Safety and efficacy have not been established in children and adolescents under 18 years of age. 6. Children: Safety and efficacy have not been established in children and adolescents under 18 years of age.

Ingredients

Manufacturer
Allico Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of essential hypertension and heart failure; reduction in the risk of death after myocardial infarction

  • Essential hypertension
  • heart failure
  • left ventricular dysfunction
  • left ventricular contractile dysfunction
View approved original text

This medication is used for the treatment of essential hypertension and heart failure. It can also be applied to heart failure patients intolerant to ACE inhibitors. It plays a crucial role in reducing the risk of mortality in patients with left ventricular dysfunction or impaired contractility after myocardial infarction. In other words, it effectively improves hypertension and cardiac function and enhances survival rates after myocardial infarction. Thus, it is generally beneficial in the treatment of cardiovascular diseases and is used to improve patients' health.

How to take

Adult dose

1. Essential hypertension Take with water during or between meals. If possible, take it at the same time each day (e.g., in the morning). 1) Adults: The recommended dose is valsartan 80 mg orally once daily, regardless of sex or race. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg daily or a diuretic may be given concomitantly. If further blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg daily. 2) Older adults (75 years and older): Start treatment with this medicine at 40 mg once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is required. (2) Creatinine clearance 10 ∼ 20 mL/min: Start treatment with this medicine at 40 mg once daily. (3) Creatinine clearance below 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with volume depletion: In patients with volume depletion (e.g., those taking high doses of diuretics whose dose cannot be reduced), start treatment with this medicine at 40 mg once daily. 5) Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, start treatment with this medicine at 40 mg once daily; do not exceed 80 mg daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg orally twice daily. The dose may be increased to 80 mg or 160 mg per dose. When administering a diuretic concomitantly, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, administered in divided doses. Triple combination therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours after the onset of myocardial infarction. The recommended starting dose is 20 mg twice daily, followed over several weeks by dose titration, according to the patient's tolerability, to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytics, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with ACE inhibitors is not recommended. 4. Patients with renal impairment: No dose adjustment is required for creatinine clearance of 10 mL/min or higher; however, do not administer this medicine to patients with creatinine clearance below 10 mL/min or to patients on dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If administering 80 mg or more daily, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.

Child dose

6) Children: Safety and efficacy have not been established in children and adolescents under 18 years of age. 6. Children: Safety and efficacy have not been established in children and adolescents under 18 years of age.

Precautions

This medication can cause serious harm to the fetus and newborn when taken during pregnancy, especially in the second and third trimesters; therefore, it should be discontinued immediately upon confirmation of pregnancy. Women who are pregnant or could become pregnant, breastfeeding women, patients with severe liver impairment, severe kidney impairment, and those with a history of certain angioedema should not take this medication. Elderly individuals or patients with hyperkalemia, patients with weak liver function, and those with heart or kidney issues should exercise special caution when taking this medication, starting at a low dose while closely monitoring the condition. This medication has a strong effect in lowering blood pressure, which can lead to a sudden drop in blood pressure during initial dosing, resulting in dizziness or fainting; therefore, patients, especially those with a deficiency in fluid or sodium, should be cautious. Patients undergoing dialysis or those on strict sodium restrictions may also have a risk of hypotension when taking this medication, so the dose should be gradually increased while monitoring their condition. During the course of taking this medication, blood pressure, kidney function, and serum potassium levels should be regularly monitored; if any abnormalities arise, appropriate measures should be taken. Taking this medication with other antihypertensives, diuretics, or potassium-sparing agents can lead to interactions that could dangerously elevate serum potassium levels, so consultation with a physician is necessary. This medication may cause dizziness while driving or operating machinery; therefore, caution is needed. In case of overdose, severe hypotension, altered consciousness, shock, etc., may occur, and immediate medical attention should be sought for proper treatment. Children and adolescents should avoid using this medication, as its safety and efficacy have not been established. The medication should be kept out of reach of children and not transferred to other containers for safety.

Side effects

headache

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container to prevent exposure to air and moisture, and kept in a cool place below 30 degrees Celsius, avoiding direct sunlight and high temperatures. By storing it this way, the efficacy of the drug can be maintained for a longer time.

Appearance and packaging

Appearance

Pink round film-coated tablet

Package unit

30 tablets per bottle, 100 tablets per bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.